Cancer cells accumulate many genetic alterations throughout their lifetime, but only a few of
them drive cancer progression, termed driver mutations. Driver mutations may vary between …

Extrachromosomal DNA (ecDNA) amplification is an important driver alteration in cancer. It
has been observed in most cancer types and is associated with worse patient outcome. The …

The APOBEC3 family of cytosine deaminases has been implicated in some of the most
prevalent mutational signatures in cancer,–. However, a causal link between endogenous …

The single-stranded DNA cytosine-to-uracil deaminase APOBEC3B is an antiviral protein
implicated in cancer. However, its substrates in cells are not fully delineated. Here …

Malignant pleural mesothelioma (MPM) is an aggressive cancer with rising incidence and
challenging clinical management. Through a large series of whole-genome sequencing …

Mutational signatures associated with apolipoprotein B mRNA-editing enzyme catalytic
polypeptide-like (APOBEC) 3 cytosine deaminase activity have been found in over half of …

Abstract Analysis of mutational signatures can reveal underlying molecular mechanisms of
the processes that have imprinted the somatic mutations found in cancer genomes. Here, we …

Blocking cancer genomic instability may prevent tumor diversification and escape from
therapies. We show that, after MAPK inhibitor (MAPKi) therapy in patients and mice bearing …

Complex genomic rearrangements (CGRs) are common in cancer and are known to form via
two aberrant cellular structures—micronuclei and chromatin bridges. However, which of …

Apolipoprotein B mRNA-editing enzyme, catalytic polypeptides (APOBECs) are cytosine
deaminases involved in innate and adaptive immunity. However, some APOBEC family …